ALLIANCE FOR AGING RESEARCH for ALLIANCE FOR AGING RESEARCH
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 3rd Quarter - Report (this page) | Oct 21, 2024 | $110,000 | Replaced |
| 3rd Quarter - Amendment | Mar 6, 2025 | $120,000 | Yes |
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
-H.R. 485 Protecting Health Care for All Patients Act of 2023 -H.R.3008 - Drug Shortage Prevention Act of 2023 -Rollout of 2024 Covid-19 vaccines -HR 2630, the Safe Step Act -H.R.8816 - American Medical Innovation and Investment Act of 2024 -Pharmacy benefit manager reform
| Lobbyist | Covered position, as disclosed |
|---|---|
| ADINA ROSE LASSER New | — |
| MICHAEL WARD | — |
Medicare/Medicaid MMM
-Implementation of Medicare Part D beneficiary affordability provisions -Nursing home quality measures -Implementation of the Medicare Direct Negotiation Program -Utilization management reform in Medicare -Beneficiary access to diabetes management devices -Vaccine access issues
| Lobbyist | Covered position, as disclosed |
|---|---|
| ADINA ROSE LASSER | — |
| MICHAEL WARD | — |
Budget/Appropriations BUD
-FY25 report language for the Food and Drug Administration -FY25 report language for the Medicare Program -FY25 report language for the Medicare Prescription Payment Plan
| Lobbyist | Covered position, as disclosed |
|---|---|
| ADINA ROSE LASSER | — |
| MICHAEL WARD | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.